Novotech Investment Limited. Novotech has made 3 investments. [singapore] clinical research and testing provider novotech on monday (mar 31) announced that temasek and gic will acquire a “significant stake in the company”, and that existing investor tpg will be reinvesting through its tpg asia fund.
Was incorporated on 22 august 2017 (tuesday) as a private company limited by shares in singapore. The reinvestment by tpg asia and investment from gic and temasek will reportedly allow novotech to pursue further organic growth and transformative m&a opportunities. Tpg asia’s reinvestment, along with investments from singapore’s gic and temasek, will help novartis further drive organic growth and pursue.
He Said The New Investment Would Allow The Company, Which Has 3000 Staff.
Novotech, founded in 1996, is the region’s biggest player in the sector thanks to more than $1 billion of investment by tpg since taking the keys eight years ago. ( novotech holdings or the company ) today announced the completion of a financing round of us$760. Novotech has raised a total funding of $255m over 5 rounds from 6 investors.
Novotech Chief Executive Officer John Moller Welcomed The New Investment And Said The Company Was Uniquely Positioned To Continue Its Growth In The Asia Pacific Region, Where Demand For.
Novotech is one of tpg’s larger investments in australia and asia, held since 2017. Novotech chief executive john moller said demand for clinical trials in asia was expected to grow by 15 per cent a year. The reinvestment by tpg asia and investment from gic and temasek will reportedly allow novotech to pursue further organic growth and transformative m&a opportunities.
Their Most Recent Investment Was On Jan 24, 2022, When Prospection Raised A New Funding Round.
The company was founded in 1996 in sydney and sold a 50 per cent stake to clark perkins’ mercury capital in.
Images References :
Novotech Chief Executive Officer John Moller Welcomed The New Investment And Said The Company Was Uniquely Positioned To Continue Its Growth In The Asia Pacific Region, Where Demand For.
He said the new investment would allow the company, which has 3000 staff. Novotech is one of tpg’s larger investments in australia and asia, held since 2017. Novotech has raised a total funding of $255m over 5 rounds from 6 investors.
Their Most Recent Investment Was On Jan 24, 2022, When Prospection Raised A New Funding Round.
Novotech, founded in 1996, is the region’s biggest player in the sector thanks to more than $1 billion of investment by tpg since taking the keys eight years ago. The reinvestment by tpg asia and investment from gic and temasek will reportedly allow novotech to pursue further organic growth and transformative m&a opportunities. Novotech chief executive john moller said demand for clinical trials in asia was expected to grow by 15 per cent a year.
Tpg Asia’s Reinvestment, Along With Investments From Singapore’s Gic And Temasek, Will Help Novartis Further Drive Organic Growth And Pursue.
The company current operating status is live with registered address at ue square. Their latest funding round was of undisclosed on mar 31, 2025. Novotech chief executive officer john moller welcomed the new investment and said the.
Novotech Has Made 3 Investments.
( novotech holdings or the company ) today announced the completion of a financing round of us$760. [singapore] clinical research and testing provider novotech on monday (mar 31) announced that temasek and gic will acquire a “significant stake in the company”, and that existing investor tpg will be reinvesting through its tpg asia fund. The reinvestment by tpg asia and investment from gic and temasek will allow novotech to pursue further organic growth and transformative m&a opportunities.
Was Incorporated On 22 August 2017 (Tuesday) As A Private Company Limited By Shares In Singapore.
The reinvestment by tpg asia and investment from gic and temasek will allow novotech to pursue further organic growth and transformative merger and acquisition ( m&a ) opportunities, the company says, “as part of its ambition to become the first truly global biotech. Gic and temasek have invested in novotech with the goal of providing funds. The company was founded in 1996 in sydney and sold a 50 per cent stake to clark perkins’ mercury capital in.
